Upside expected for Ancom bottom line post-Brazil herbicide approval

TheStar Fri, Jul 24, 2026 12:00am - 1 month View Original


Kenanga Research expects the company to deliver 10% to 16% year-on-year growth in core earnings per share over FY27 and FY28.

PETALING JAYA: Stronger demand for Ancom Nylex Bhd’s herbicide, monosodium methanearsonate (MSMA), following approval for use in Brazil’s soybean crop, will drive the company’s core earnings per share growth for the financial years ending May 31, 2027 (FY27) and FY28.

Kenanga Research expects the company to deliver 10% to 16% year-on-year (y-o-y) growth in core earnings per share over FY27 and FY28.

The research house maintained its “outperform” call and target price of RM1.50 per share after the company’s post-FY26 results briefing, while keeping its FY27 and FY28 earnings forecasts unchanged.

Earnings growth would come from MSMA expansion in Brazil, continued orders for its timber preservative business, growing contributions from new active ingredients and still healthy industrial chemical earnings, it said.

...

Full Article on TheStar

The content is a snapshot from Publisher. Refer to the original content for accurate info. Contact us for any changes.






Related Stocks

ANCOMNY 0.875

Comments

Login to comment.